Bispecific Antibodies: A Novel Approach for the Treatment of Solid Tumors

Area of Science:

• Oncology
• Immunotherapy
• Molecular Biology

Background:

• Targeted therapies, including monoclonal antibodies (mAbs), have improved cancer patient outcomes by targeting specific oncogenic proteins.
• Resistance to mAb therapy often arises from alternative pathway activation and immune evasion, limiting long-term efficacy.
• Bispecific antibodies (bsAbs) are engineered to overcome resistance by simultaneously targeting multiple cancer-driving molecules or immune checkpoints.

Purpose of the Study:

• To review the current landscape of bispecific antibodies (bsAbs) for treating solid tumors.
• To outline the classification, design, production technologies, and mechanisms of action of bsAbs.
• To present updated clinical evidence and discuss the limitations of bsAbs in solid malignancies.

Main Methods:

• Comprehensive literature review of bispecific antibody research and clinical trials in solid tumors.
• Analysis of bsAb design strategies, production methodologies, and mechanisms of action.
• Synthesis of current clinical data and identification of challenges and future directions.

Main Results:

• Several bsAbs are under investigation for solid tumors, with some approved for hematologic malignancies.
• bsAbs demonstrate potential by engaging multiple targets, including tumor-associated antigens and immune modulators.
• Challenges remain in optimizing bsAb efficacy and overcoming resistance in the context of solid tumors.

Conclusions:

• Bispecific antibodies represent a significant advancement in cancer therapy, offering a strategy to combat treatment resistance in solid tumors.
• Further research and clinical trials are crucial to realize the full therapeutic potential of bsAbs against solid malignancies.
• Understanding bsAb design, production, and clinical performance is key to their successful implementation.